Actively Recruiting
Comparing Donepezil Medication and Non-Drug Treatments for Early Alzheimers Disease in Adults 50 and Older
Led by Assistance Publique - Hôpitaux de Paris · Updated on 2026-02-18
240
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are comparing two treatment approaches for people with Alzheimers disease a non-drug method based on cognitive stimulation and remediation, and a drug treatment using Donepezil. This study aims to see how well these approaches improve symptoms after six months, especially since Donepezil is no longer reimbursed by the French healthcare system. The trial is randomized, open-label, and multicentric, focusing on patients newly diagnosed with Alzheimers disease. Participants are assigned to one of two groups. The first group receives standard care involving cognitive, psychological, functional, and social support, including cognitive stimulation sessions with speech therapists and mobile specialist teams at home. The second group receives the same non-drug approach plus Donepezil tablets, starting at 5 mg daily for one month and increasing to 10 mg daily for the remaining five months. During the 26-week study, participants will undergo various assessments such as the Mini-Mental State Examination MMSE, Alzheimers Disease Assessment Scale-Cognitive ADAS-Cog, Clinical Dementia Rating CDR, Activities of Daily Living ADL, quality of life, and caregiver burden ZARIT scale. Researchers will monitor changes in these measures to evaluate treatment effects. The trial includes safety monitoring and follow-up over the full six months.
CONDITIONS
Brief Title
Donepezil Versus Non-drug Treatment in Alzheimer's Disease.
Research Team
D
DUMURGIER Julien, MD, PhD
P
PAQUET Claire, MD, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here